Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.15 - $12.37 $177,320 - $306,776
24,800 Added 1180.95%
26,900 $236,000
Q2 2024

Aug 14, 2024

SELL
$6.49 - $19.2 $76,582 - $226,560
-11,800 Reduced 84.89%
2,100 $25,000
Q1 2024

May 15, 2024

BUY
$17.99 - $30.49 $62,964 - $106,715
3,500 Added 33.65%
13,900 $253,000
Q4 2023

Feb 14, 2024

SELL
$11.67 - $33.01 $288,249 - $815,347
-24,700 Reduced 70.37%
10,400 $326,000
Q3 2023

Nov 14, 2023

BUY
$13.56 - $18.47 $336,288 - $458,056
24,800 Added 240.78%
35,100 $532,000
Q2 2023

Aug 14, 2023

SELL
$8.57 - $15.44 $53,134 - $95,728
-6,200 Reduced 37.58%
10,300 $159,000
Q1 2023

May 15, 2023

BUY
$7.08 - $19.4 $97,704 - $267,720
13,800 Added 511.11%
16,500 $153,000
Q4 2022

Feb 14, 2023

BUY
$8.94 - $18.35 $24,138 - $49,545
2,700 New
2,700 $49,000

Others Institutions Holding CVRX

About CVRx, Inc.


  • Ticker CVRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 20,576,200
  • Market Cap $286M
  • Description
  • CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The co...
More about CVRX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.